A detailed history of Ubs Oconnor LLC transactions in Allakos Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 777,702 shares of ALLK stock, worth $917,688. This represents 0.03% of its overall portfolio holdings.

Number of Shares
777,702
Holding current value
$917,688
% of portfolio
0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.54 - $0.92 $33,013 - $56,246
61,137 Added 8.53%
777,702 $505,000
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.45 $74,900 - $108,605
74,900 Added 11.67%
716,565 $716,000
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $654,498 - $2.07 Million
641,665 New
641,665 $808,000
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $649,388 - $1.88 Million
20,948 New
20,948 $1.65 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $100M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.